Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1B2 | O75343 | 2/20 | 0.37 |
| ▸ | GUCY1A2 | P33402 | 2/20 | 0.37 |
| ▸ | GUCY1A1 | Q02108 | 2/20 | 0.37 |
| ▸ | GUCY1B1 | Q02153 | 2/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.36 |
| ▸ | GPR88 | Q9GZN0 | 3/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 6/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14437218 | 0.88 | HPGD (0.38) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1IRAK4 | |
| SCHEMBL3025813 | 0.87 | EGFR (0.37) | PDPK1 | |
| SCHEMBL5509030 | 0.87 | EGFR (0.38) | MET | |
| SCHEMBL5506217 | 0.85 | MAPK1 (0.35) | IRAK4PDPK1MET | |
| SCHEMBL5511506 | 0.82 | KDM1A (0.36) | IRAK4PDPK1MET | |
| SCHEMBL5507148 | 0.79 | CCNB2 (0.38) | IRAK4PDPK1 | |
| SCHEMBL5504200 | 0.78 | MAPK1 (0.36) | — | |
| SCHEMBL13233381 | 0.75 | MEN1 (0.42) | — | |
| SCHEMBL13898543 | 0.75 | MEN1 (0.42) | — | |
| SCHEMBL14437205 | 0.74 | EGFR (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253285-B2 | Thiazolinone 4-monosubstituted quinolines | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | claimed |
| EP-1797085-A1 | THIAZOLINONE 4-MONOSUBSTITUTED QUINOLINES | F. Hoffmann-Roche AG (CH) | 2007-06-20 | — | — | EP | claimed |
| US-20060063805-A1 | Thiazolinone 4-monosubstituted quinolines | CHEN LI | 2006-03-23 | — | — | US | claimed |
| WO-2006029861-A1 | THIAZOLINONE 4-MONOSUBSTITUTED QUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-23 | — | — | WO | claimed |
| US-7253285-B2 | Thiazolinone 4-monosubstituted quinolines | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| EP-1797085-A1 | THIAZOLINONE 4-MONOSUBSTITUTED QUINOLINES | F. Hoffmann-Roche AG (CH) | 2007-06-20 | — | — | EP | disclosed |
| US-20060063805-A1 | Thiazolinone 4-monosubstituted quinolines | CHEN LI | 2006-03-23 | — | — | US | disclosed |
| WO-2006029861-A1 | THIAZOLINONE 4-MONOSUBSTITUTED QUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063805-A1 | Thiazolinone 4-monosubstituted quinolines | CDK1, CDK14, CDK17 | GUCY1B2 4786/4885GUCY1A2 4807/4885GUCY1A1 4739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.